Funding Announcements

"We live in a society that’s created an unsustainable pattern of living where workplace culture is synonymous with burnout and stress is seen as a necessary by-product of success. The past 18 months have put a much-needed spotlight on the terrible impact of stress on our health, and for the first time, employers are taking notice."

"Mental health has been an overlooked area of care and wellbeing, especially in the workplace. Oliva’s founders are the only team we’ve seen taking a holistic, impact-driven approach to supporting mental health. While employer-funded mental health is becoming a well established model in the US, Oliva is the first to bring a truly comprehensive approach to UK and European businesses. Oliva has already built a strong value proposition, team and product to create a new model for mental healthcare in the UK, Europe and beyond."

"It’s been a landmark year for Reacta, and we continue to go from strength-to-strength as a business, developing new diagnostic products and expanding our capabilities. The number of people experiencing food allergies is increasing, so it’s vital that technologies to accurately and safely test for allergies are developed. We’re committed to providing excellence in the development of a suite of OFC products, and revolutionising the way food allergies are diagnosed worldwide."

"One reason for the recent decline in the uptake of rapid Covid-19 tests is the sampling technique – it’s currently very uncomfortable and difficult for people to use. We need to take the pain out of mass testing if we’re to return to normal to minimise the disruption caused by future COVID-19 outbreaks, whether in offices, schools or hospitality venues. That’s why we’ve built supportive bio security technology that sits alongside the test, allowing users to generate their own unique QR codes to facilitate safe venue entry."

"People living with cancer experience a wide range of physical and psychosocial effects. Despite the fantastic treatment traditional healthcare providers offer, they’re not well-equipped to manage these diverse, on-going, personalised needs thereafter – and once the primary cancer treatment has come to an end, many people describe feeling ‘abandoned’."